靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2021.01.015

Abstract

Abstract: Fibroblast growth factor receptors(FGFRs)regulates cell growth,proliferation and angiogenesis by binding with ligand fibroblast growth factors(FGFs).More and more studies have shown that FGFRs are the driving factor of some malignant tumors,and play an important role in the process of tumor angiogenesis and tumor cell division and proliferation.This article reviews the mechanism of FGFRs signaling pathway in physiology,pathology and malignant tumor,and provides a basis for clinical development for targeted inhibition of FGFRs signaling and the improvement of tumor treatment programs.

Key words: Fibroblast growth factors, Malignant tumors, Mechanism of action, Targeted therapy

CLC Number:

YANG Siqi,SONG Qibin,LI Qingqing,YAO Yi. Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors[J]. Journal of Practical Oncology, 2021, 35(1): 73-77.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/73

References

1 Babina IS,Turner NC.Advances and challenges in targeting FGFR signalling in cancer[J].Nat Rev Cancer,2017,17(5):318.
2 Nobuyuki I,Ornitz DM.Fibroblast growth factors:from molecular evolution to roles in development,metabolism and disease[J].J Biochem,2011,149(2):121-130.
3 邢志超,麦威.脂肪肉瘤潜在作用靶点的研究进展[J].实用肿瘤学杂志,2019,33(1):88-92.
4 Perez-Garcia J,Muoz-Couselo E,Soberino J,et al.Targeting FGFR pathway in breast cancer[J].Breast,2017,37(7):126-133.
5 Fan JY,Li YW,Jia RB,et al.An inherited FGFR2 mutation increased osteogenesis gene expression and result in Crouzon syndrome[J].BMC Med Gene,2018,19(1):91.
6 Zhang Y,Zheng DF,Li Y,et al.Comprehensive investigation of clinicopathologic features,oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma[J].J Thorac Dis,2017,9(11):4434.
7 Yang Z,Zhang RY,Ge YX,et al.Somatic,FGFR3,mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy[J].Ebiomedicine,2018,35(5):25-30.
8 Hanker AB,Garrett JG,Estrada MV,et al.HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2[J].Clin Cancer Res,2017,23(15):4323-4334.
9 Montor WR,Salas AROSE,de Melo FHM.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment:the current arsenal of inhibitors[J].Mol Cancer,2018,17(1):55.
10 Sobhani N,Ianza A,D'Angelo A,et al.Current status of fibroblast growth factor receptor-targeted therapies in breast cancer[J].Cells,2018,7(7):76.
11 Yang W,Yao YW,Zeng JL,et al.Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer:A meta-analysis[J].J Thorac Dis,2014,6(6):803-809.
12 Malchers F,Ercanoglu M,Schütte D,et al.Mechanisms of primary drug resistance in FGFR1 amplified lung cancer[J].Clin Cancer Res,2017,23(18):78-80.
13 Ishiwata T,Yoshiruma H,Matsuda Y,et al.Abstract 4577:Fibroblast growth factor receptor-4(FGFR-4)as a novel therapeutic target for pancreatic cancer[J].Cancer Res,2016,76(14):4577-4577.
14 Lamont FR,Tomlison DC,Cooper PA,et al.Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.[J].British J Cancer,2011,104(1):75-82.
15 De Luca A,Frezzetti D,Gallo M,et al.FGFR-targeted therapeutics for the treatment of breast cancer[J].Expert Opin Inv Drugs,2017,26(3):303.
16 Hu P,Chen H,Mcgowan E,et al.Assessment of FGFR1 overexpression and over-activity in lung cancer cells:a toolkit for anti-FGFR1 drug screening[J].Hum Gene Ther Method,2017,18(4):227-229.
17 刘佳骅,倪醒之.成纤维细胞生长因子受体4在恶性肿瘤中的作用[J].实用医学杂志,2010,26(3):511-512.
18 Hu Y,Hsu W.FGFR1/MAPK pathway regulates transcription factor brachyury-driven epithelial-mesenchymal transition in lung cancer[J].Cancer Res,2015,75(15):2079.
19 Tsunoda S,Nakamura T,Sakurai H,et al.Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization[J].Cancer Sci,2007,98(4):541-548.
20 Thomson S,Petti F,Sujka-Kwok I,et al.Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy[J].Clin Exp Metastas,2008,25(8):843-854.
21 Xu M,Chen S,Yang W,et al.FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer[J].Cell Physio Biochem,2018,47(1):151-160.
22 Sun C,Fang L,Gou S.Discovery of a Novel FGFR4 Selective Inhibitor via Structure-Activity Relationship Studies of FGF401[J].Chinese J Org Chem,2020,40(1):84.
23 Piasecka D,Braun M,Kitowska K,et al.FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors-implications for therapy of luminal breast cancer[J].J Experimental Clin Cancer Res,2019,38(230): 1-12.
24 Mcleskey SW,Powers CJ,Wellstein A.Fibroblast growth factors,their receptors and signaling[J].Endocrine Related Cancer,2000,7(3):165-197.
25 Moyal CJ,Ader I,Delmas C,et al.Targeting FGFR-1 pathways by the antagonist SSR128129E overcomes the radioresistance of human glioma in vitro and in vivo[J].Int J Radiat Oncol,2009,75(3):70.
26 Darren RC,Rebekah HG,Yu X,et al.Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres[J].J Vasc Intervl Radiol,2014,25(2):297-306.
27 Grünewald S,Politz O,Bender S,et al.Rogaratinib:a potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models[J].Int J Cancer,2019,145(5):1346-1357.
28 Kikuchi A,Suzuki T,Nakazawa T,et al.ASP5878,a selective FGFR inhibitor,to treat FGFR3-dependent urothelial cancer with or without chemoresistance[J].Cancer Sci,2017,108(2):236-242.
29 Tiseo M.FGFR as potential target in the treatment of squamous non small cell lung cancer[J].Cancer Treat Rev,2015,41(6):527-539.
30 Nogova L,Sequist LV,Perez Garcia JM,et al.Evaluation of BGJ398,a fibroblast growth factor receptor 1-3 kinase inhibitor,in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors:results of a global phase I,dose-escalation and dose-expansion study[J].J Clin Oncol,2016,35(2):48-50.
31 Wen J,Xue Y,Ming T,et al.Recent developments and advances of FGFR as a potential target in cancer.[J].Future Med Chem,2018,10(17):103-105.
32 Brummelen EMJV.A phase Ib study of GSK3052230,an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma[J].Future Med Chem,2019,16(5):15-19.
33 Goyal L,Saha SK,Liu LY,et al.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma[J].Cancer Discov,2017,7(3):1000-1016.
34 Brands R,Knierim L,De Donno F,et al.Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro[J].Oncol Rep,2017,38(3):1877-1885.
35 Javle M,Lowery M,Shroff RT,et al.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J].J Clin Oncol,2018,36(3):509-511.
36 Liang D,Chen Q,Guo Y,et al.Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study[J].Drug Des Dev Ther,2017,11(6):451-461.
37 Kelly CM,Shoushtari AN,Qin LX,et al.A phase Ib study of BGJ398,a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor[J].Invest New Drugs,2019,37(2):282-290.
38 Wu D.LY2874455 potently inhibits FGFR gatekeeper mutant and overcomes mutation-based resistance[J].Chem Commun,2018,54(85):12089-12092.
39 Santoni-Rugiu E,Grauslund M,Melchior LC,et al.Heterogeneous resistance mechanisms in an,EGFR,exon 19-mutated non-small cell lung cancer patient treated with erlotinib:persistent,FGFR3-mutation,localized transformation to,EGFR-mutated SCLC,and acquired T790M,EGFR-mutation[J].Lung Cancer,2017,113(8):14-17.
40 Baschnagel AM,Li C,Morgan AM,et al.Abstract 1094:Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma[J].Cancer Res,2017,77(13):1094-1094.
41 Packer LM,Geng X,Bonazzi VF,et al.PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2-mutant endometrial cancers[J].Mol Cancer Ther,2017,16(4):637-648.
42 Kristina G,Lydia M,Mirjam K,et al.Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer[J].Oncogene,2018,37(3):5682-5693.
43 Sun Y K,Ahn T,Bang H,et al.Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion[J].Oncotarget,2017,8(9):1182-1186.
44 Yu Y,Hall T,Eathiraj S,et al.In-vitro and in-vivo combined effect of ARQ 092,an AKT inhibitor,with ARQ 087,a FGFR inhibitor[J].Anticancer Drug,2017,28(5):503-513.

[1]	SONG Jiayu, FENG Yue, WANG Zhao, ZHANG Yunyan. The latest research progress of the correlation between exosomes and gynecological malignant tumor [J]. Journal of Practical Oncology, 2020, 34(6): 571-575.
[2]	FAN Xiaona,WANG Dan,LI Qingwei,LI Zhiwei. Advances in research on adjuvant drug threapy for postoperative pancreatic cancer [J]. Journal of Practical Oncology, 2020, 34(3): 249-253.
[3]	LI Guozheng, PANG Da. Progression in the treatment of HER2-positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(1): 74-78.
[4]	ZUO Zhibo, GUO Zhiqin, WANG Zhen, YANG Hongjie, WU Wanxin. Research progress of Semaphorin 3F in tumors [J]. Journal of Practical Oncology, 2020, 34(1): 88-92.
[5]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[6]	CHEN Hongbo, YU Zengrong, DING Xiaofan, XIAO Lin. Progress of correlation between bone marrow dose-volume parameters and acute hematologic toxicity in pelvic malignant tumor [J]. Journal of Practical Oncology, 2019, 33(4): 361-366.
[7]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[8]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[9]	ZHOU Jie, CHEN Yu, CHEN Daozhen. Application of nanoparticles in photodynamic therapy of tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 245-249.
[10]	ZHANG Yongxin, HUANG He. Research progress and mechanism of Galectin-9 and various malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 159-163.
[11]	HUANG Qianqian, MA Jianjia, WU Qiang, LIU Binbin, MU Xiaoqin, LIU Shulin. Research progress on tumor stem cells and tumor targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 533-537.
[12]	HAN Xuejiao, LI Yanchun, SUN lichun, LU Hailing. Research progress of the relationship between 14-3-3ζ and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 543-547.
[13]	SUN Yuqi,CHEN Xiuwei. Research progress of CTGF/CCN2 in the development and targeted therapy of malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 363-366.
[14]	FAN Mingxv, ZHAO Yanbin, LI Boyang, WANG Yan. Research progress in the Notch pathway in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 57-60.
[15]	ZUO Zhichao, SU Danke, DENG Wenjuan, JIN Guanqiao. Recent advances of ELAM-1 in targeted cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 444-447.

Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments